Astrocytoma, IDH-Mutant, Grade 4 — Trials

Astrocytoma, IDH-Mutant, Grade 4 — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 12
Recruiting: 9
Ph III recruiting: 1
Growth YoY: —
Industry share: 8%
Top sponsor: Mayo Clinic
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06860594	Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma	recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	1	Sep 2, 2026	clinicaltrials
NCT07544992	Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas	recruiting	Phase 1	24	City of Hope Medical CenterOTHER	1	Aug 12, 2026